{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:53:59Z","timestamp":1779206039107,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.canlet.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T21:01:15Z","timestamp":1476824475000},"page":"243-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth"],"prefix":"10.1016","volume":"385","author":[{"given":"Raghavendra","family":"Gowda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arati","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-6715","authenticated-orcid":false,"given":"Gavin P.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.10.016_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.10.016_bib2","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.10.016_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.10.016_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fphar.2013.00068","article-title":"Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy","volume":"4","author":"Crawford","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2016.10.016_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.10.016_bib6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2010.408","article-title":"Hyperactivation of MEK-ERK1\/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells","volume":"30","author":"Kaplan","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2016.10.016_bib7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.10.016_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","article-title":"From genes to drugs: targeted strategies for melanoma","volume":"12","author":"Flaherty","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.10.016_bib9","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-14-3763","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method\u2014letter","volume":"75","author":"Ashton","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jnci\/94.8.545","article-title":"COX-2 in cancer\u2014a player that's defining the rules","volume":"94","author":"Hawk","year":"2002","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2016.10.016_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1734-1140(10)70262-0","article-title":"COX-2 as a target for cancer chemotherapy","volume":"62","author":"Ghosh","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.canlet.2016.10.016_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-12-0492","article-title":"Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma","volume":"12","author":"Gowda","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.10.016_bib13","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/ijc.23315","article-title":"Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells","volume":"122","author":"Xiao","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.10.016_bib14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ijc.24766","article-title":"Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells","volume":"126","author":"Yang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.10.016_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ijc.23718","article-title":"Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention","volume":"123","author":"Xiao","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.10.016_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2016.10.016_bib17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molonc.2012.12.001","article-title":"Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model","volume":"7","author":"Hafeez","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2016.10.016_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1940-6207.CAPR-14-0231","article-title":"Plumbagin inhibits prostate carcinogenesis in intact and castrated PTEN knockout mice via targeting PKCepsilon, Stat3, and epithelial-to-mesenchymal transition markers","volume":"8","author":"Hafeez","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00216-006-0502-6","article-title":"UV\/Vis spectra and solubility of some naphthoquinones, and the extraction behavior of plumbagin from Plumbago scandens roots in supercritical CO2","volume":"385","author":"Rodrigues","year":"2006","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.canlet.2016.10.016_bib20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4248\/BR201304007","article-title":"Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions","volume":"1","author":"Yan","year":"2013","journal-title":"Bone Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2010.05.013","article-title":"Plumbagin-induced apoptosis in lymphocytes is mediated through increased reactive oxygen species production, upregulation of Fas, and activation of the caspase cascade","volume":"247","author":"McKallip","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.canlet.2016.10.016_bib22","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/1535-7163.MCT-14-0357","article-title":"Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma","volume":"13","author":"Gowda","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.10.016_bib23","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1158\/1535-7163.MCT-13-0867","article-title":"Targeting multiple key signaling pathways in melanoma using leelamine","volume":"13","author":"Gowda","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.10.016_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib25","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/1535-7163.MCT-13-0868","article-title":"Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport","volume":"13","author":"Kuzu","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.10.016_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-148X.2012.00970.x","article-title":"Targeting sphingosine kinase-1 to inhibit melanoma","volume":"25","author":"Madhunapantula","year":"2012","journal-title":"Pigment. Cell Melanoma Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib27","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1158\/0008-5472.CAN-07-6614","article-title":"Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development","volume":"68","author":"Tran","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2012.12.019","article-title":"Identification of aurora kinase B and WEE1 as downstream targets of (V600E)B-RAF in melanoma","author":"Sharma","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2016.10.016_bib29","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-07-5867","article-title":"Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development","volume":"68","author":"Cheung","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/1758834012463260","article-title":"New treatment approaches in melanoma: current research and clinical prospects","volume":"5","author":"Rughani","year":"2013","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2016.10.016_bib31","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2016.10.016_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-014-0083-7","article-title":"A\u00a0review of novel therapies for melanoma","volume":"15","author":"Karimkhani","year":"2014","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.canlet.2016.10.016_bib33","first-page":"1493","article-title":"New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies","volume":"34","author":"Azijli","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib34","series-title":"First Approval for First PD Inhibitor: Nivolumab for Melanoma","author":"Chustecka","year":"2014"},{"key":"10.1016\/j.canlet.2016.10.016_bib35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s40265-014-0234-4","article-title":"Nivolumab: a review of its use in patients with malignant melanoma","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2016.10.016_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28851","article-title":"The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition","author":"Chan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2016.10.016_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11912-013-0336-2","article-title":"MEK inhibition in the treatment of advanced melanoma","volume":"15","author":"Salama","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2016.10.016_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/DHPS.S39568","article-title":"New developments in the treatment of metastatic melanoma \u2013 role of dabrafenib-trametinib combination therapy","volume":"6","author":"Luke","year":"2014","journal-title":"Drug, Healthc. Patient Saf."},{"key":"10.1016\/j.canlet.2016.10.016_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.10.016_bib40","first-page":"62","article-title":"Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma","volume":"55","year":"2013","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.canlet.2016.10.016_bib41","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2016.10.016_bib43","article-title":"Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab","author":"Stephen Hodi","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.10.016_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by Celecoxib in cancer","volume":"332","author":"Jendrossek","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.10.016_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/10717544.2012.724472","article-title":"Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib","volume":"19","author":"Bragagni","year":"2012","journal-title":"Drug Deliv."},{"key":"10.1016\/j.canlet.2016.10.016_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/13543784.17.2.197","article-title":"Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs","volume":"17","author":"Schonthal","year":"2008","journal-title":"Expert Opin. Investig Drugs"},{"key":"10.1016\/j.canlet.2016.10.016_bib47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/med.20235","article-title":"Perspectives on medicinal properties of plumbagin and its analogs","volume":"32","author":"Padhye","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.canlet.2016.10.016_bib48","doi-asserted-by":"crossref","first-page":"e55509","DOI":"10.1371\/journal.pone.0055509","article-title":"Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27\/p38\/AKT pathways and by inhibiting ABCB1","volume":"8","author":"Sims","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2016.10.016_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/jid.2013.32","article-title":"Stat3-targeted therapies overcome the acquired resistance to Vemurafenib in melanomas","author":"Liu","year":"2013","journal-title":"J.\u00a0Investig. Dermatol."},{"key":"10.1016\/j.canlet.2016.10.016_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-005-1580-1","article-title":"Targeting STAT3 affects melanoma on multiple fronts","volume":"24","author":"Kortylewski","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2016.10.016_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CMR.0b013e32831d7f52","article-title":"COX-2 expression in malignant melanoma: a novel prognostic marker?","volume":"19","author":"Becker","year":"2009","journal-title":"Melanoma Res."},{"key":"10.1016\/j.canlet.2016.10.016_bib52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5193(05)80233-4","article-title":"The theory of the frequency response of ellipsoidal biological cells in rotating electrical fields","volume":"148","author":"Paul","year":"1991","journal-title":"J.\u00a0Theor. Biol."},{"key":"10.1016\/j.canlet.2016.10.016_bib53","doi-asserted-by":"crossref","first-page":"36167","DOI":"10.1074\/jbc.M203184200","article-title":"STAT3 down-regulates the expression of cyclin D during liver development","volume":"277","author":"Matsui","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.10.016_bib54","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1038\/sj.onc.1204270","article-title":"Cyclin G1 is involved in G2\/M arrest in response to DNA damage and in growth control after damage recovery","volume":"20","author":"Kimura","year":"2001","journal-title":"Oncogene"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T01:04:19Z","timestamp":1718845459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516306280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":54,"alternative-id":["S0304383516306280"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.10.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}